gkk1 ards g.k.kumar. gkk2 ards definition epidemiology patient presentation and diagnosispatient...
TRANSCRIPT
gkk 2
ARDS• Definition • Epidemiology• Patient presentation and diagn
osis
• Pathophysiology • Treatment • Complications
gkk 3
Historical background • First described in 1967 by
Ashbaugh et al Consensus after 1994 • In 1994 a new definition was
recommended by the American-European Consensus Conference Committee.
gkk 4
DefinitionARDS is characterized by• Acute onset • Bilateral infiltrates on chest
radiograph • Pulmonary artery wedge
pressure < 18 mmHg; if unavailable, then lack of clinical evidence of left ventricular failure suffices
• PaO2:FiO2 < 200 mmHg
gkk 6
Epidemiology• The annual incidence of ARDS 1.5 to 13.5
people per 100,000 in the general population. In mechanically ventilated population is much higher.
• (ALI) of 16.1% in ventilated patients admitted for more than 4 hours.
• More than half these patients may develop ARDS
- Brun-Buisson et al. (2004)
gkk 7
Risk factors• Mechanical ventilation, sepsis, pneumonia,
shock, aspiration, trauma (especially pulmonary contusion), major surgery, massive transfusions, smoke inhalation, drug reaction or overdose, fat emboli and reperfusion pulmonary edema after lung transplantation or pulmonary embolectomy. Pneumonia and sepsis are the most common triggers, and pneumonia is present in up to 60% of patients.
• Elevated abdominal pressure of any cause is also probably a risk factor for the development of ARDS, particularly during mechanical ventilation.
gkk 9
Predisposing FactorsPulmonary conditions • Severe pneumonia. • Aspiration • Near drowning. • Inhalation of toxins and other irritants
such as smoke. • Lung injury and bruising. • Oxygen toxicity. • Fat embolism- Where bubbles of fat
travel through the bloodstream and block off airways.
gkk 10
Predisposing FactorsSystemic conditions • Shock- Including septic shock and shock due to trauma. • Septicaemia. • Burns. • Pancreatitis. • Diabetic Ketoacidosis. • Hypersensitivity reactions. • Drugs reactions due to aspirin, heroin or paraquat. • Multiple blood transfusions. • Malaria. • Acute liver failure. • Obstetric complications- Problems during pregnancy or
delivery such as preeclampsia. • Cardiac surgery and other complicated surgeries.
Patient presentation Patient presentation and diagnosisand diagnosis
Patient presentation Patient presentation and diagnosisand diagnosis
gkk 12
• ARDS usually occurs within 24 to 48 hours of the initial injury or illness.
• The patient usually presents with shortness of breath, tachypnea, and symptoms related to the underlying cause, i.e. shock
Patient presentation and diagnosis
gkk 13
Patient presentation and diagnosis
• Arterial blood gas analysis• Chest X-ray• Pulmonary artery catheter for
measuring the pulmonary artery wedge pressure.
• CT scanning
gkk 16
Pathophysiology• Diffuse inflammation of lung
parenchyma• Typical histological presentation
involves diffuse alveolar damage and hyaline membrane formation in alveolar walls.
gkk 17
Pathophysiology
• Endothelial dysfunction, fluid extravasation from the capillaries and impaired drainage of fluid from the lungs.
• This pulmonary edema increases the thickness of the alveolo-capillary space.
• This impairs gas exchange leading to hypoxia, increases the work of breathing, eventually induces fibrosis of the airspace.
gkk 18
Pathophysiology• Dysfunction of type II pulmonary
epithelial cells, with a concomitant reduction in surfactant production.
• Edema and decreased surfactant production by type II pneumocytes may cause whole alveoli to collapse, or to completely flood.
gkk 19
Pathophysiology• This loss of aeration contributes
further to the right-to-left shunt, resulting in massive intrapulmonary shunting.
• The loss of aeration may follow different patterns according to the nature of the underlying disease, and other factors
gkk 20
Pathophysiology• In pneumonia-induced ARDS,
infiltrates are usually distributed to the lower lobes, in their posterior segments, and they roughly correspond to the initial infected area.
gkk 21
Pathophysiology• In sepsis or trauma-induced ARDS,
infiltrates are usually more patchy and diffuse. The posterior and basal segments are always more affected, but the distribution is even less homogeneous.
gkk 23
Treatment
• Mechanical ventilation• Antibiotic• When sepsis is diagnosed,
appropriate protocols should be enacted.
gkk 24
Mechanical ventilation• The overall goal is to maintain acceptable gas
exchange and to minimize adverse effects in its application.
• Three parameters are used: PEEP, to maintain maximal recruitment of
alveolar units. Mean airway pressure (to promote
recruitment and predictor of hemodynamic effects)
Plateau pressure (best predictor of alveolar overdistention).
gkk 25
Mechanical ventilationVARIABLES NIH-ARDS NETWORK PROTOCALS
TIDAL VOLUME ≤6 ml/kg
PLEATAU PRESSURE
≤30 cm H2O
VENTILATION SET RATE/ pH GOAL
6-35/ min to achieve pH ≥7.30
INSPIRATORY FLOW,I:E RATIO
Flow to achieve I:E Ratio 1:1-1:3
OXYGENATION GOAL
PaO2 ≥55mmHg,SpO2 ≥88%
FiO2/PEEP 0.3/5, 0.4/5-8, 0.5/8-10, 0.6/10,0.7/10-14, 0.8/14, 0.9/14-18,1/18-24
WEANING When FiO2/PEEP 0.4/8 ,with PSV
gkk 26
• Low tidal volume ventilation • Plateau pressure less than 30 cm
H2O was a secondary goal, • APRVis the primary mode of
choice when ventilating a patient with ARDS or ALI.
Mechanical ventilation
gkk 27
AIRWAY PRESSURE RELEASE VENTILATION(APRV)
• A CPAP circuit with release valve at expiratory limb –driven by time device
• APRV is a CPAP system causing . alveolar ventilation by briefly interrupting CPAP.
gkk 28
APRV• Release valve opens for 1-2sec.• Pr drops to lower level-low CPAP(0to-
2cmH2O)• Lung volume less than FRC in expiration• alveolar ventilation & CO2 elimination• Reapplication of CPAP by closing valve-
Higher CPAP(10to 12 cm H2O)• FRC & oxygenation.
gkk 29
APRV• ADVANTAGES:• Lesser PIP ,so less hemo dynamic
changes.• To alveolar ventilation in ALI of
mild to moderate.• A weaning mode.
gkk 30
Advantages to APRV ventilation• decreased airway pressures,• decreased minute ventilation, • decreased dead-space ventilation,• promotion of spontaneous breathing, near
elimination of neuromuscular blockade • almost 24 hour a day alveolar recruitment, • decreased use of sedation, • positive effect on cardiac output (due to the
negative inflection from the elevated baseline with each spontaneous breath).
• A patient with ARDS on average spends 8 to 11 days on a mechanical ventilator; APRV may reduce this time significantly.
Mechanical ventilation
gkk 31
INVERSE RATIO VENTILATION(IRV)
•I:E >1
•PC-IRV / VC-IRV
• Ti with set pr opening of stiff alveoli units improved oxygenation
• Te not allowing alveoli to collapse
development of intrinsic PEEP
reduction of shunting
gkk 32
IRV……,Improve oxygenation by
•Reducing intra pulmonary shunting
•Improvement of V/Q matching
•Decreased dead space ventilation
•Increased MAP & intrinsic PEEP
Useful when high FiO2 & high PEEP to be avoided
gkk 33
Inverse ratio ventilation
• Inverse ratio ventilation is reserved for severe cases when it is impossible to oxygenate the patient adequately.
• Treatment involves increasing the amount of time that the ventilator is inspiring versus expiring.
• Patients normally spend more time exhaling than inhaling, at a ratio of about 3:1. Increasing the amount of time spent inhaling re-expands more collapsed alveoli than positive pressure alone.
• This is an uncomfortable technique and usually requires sedation and a muscle-paralyzing drug that keeps the respiratory muscles from resisting the unnatural inverse ratio ventilation.
gkk 34
• Distribution of lung infiltrates in acute respiratory distress syndrome is non-uniform.
• Repositioning into the prone position (face down) might improve oxygenation by relieving atelectasis and improving perfusion.
Prone position ventilation
gkk 35
• Improved V/P in previously atelectactic areas due to uniform distribution of plural pr -Lamm etall
• Requires atleast more than 6 hrs/ day of prone ventilation.
• A significant decrease in right ventricular enlargement and a significant reduction in septal dyskinesia, after 18 h of prone positioning.-Vielliard etall ,CHEST-OCT-2007
• No improvement in mortality in clinical trials
Prone position ventilation
gkk 36
Fluid management
• Several studies have shown that pulmonary function and outcome are better in patients that lost weight or wedge pressure was lowered by diuresis or fluid restriction
gkk 37
Corticosteroid
• Steroids cause a suppression of inflammation during the fibroproliferative phase of ARDS. The initial regimen consists of mps 2 mg/kg daily. After 3-5 days a response must be apparent. In 1-2 weeks the dose can be tapered to mps 0.5-1.0 mg daily. In the absence of results steroids can be discontinued.-Meduri et al
• ARDSnet LAZARUS study demonstrated that they are not efficacious in ARDS.
gkk 38
Nitric oxide
• Inhaled nitric oxide (NO) potentially acts as selective pulmonary vasodilator. Rapid binding to hemoglobin prevents systemic effects. It should increase perfusion of better ventilated areas. There are no large studies demonstrating positive results.
• Almitrine bismesylate stimulates chemoreceptors in carotic and aortic bodies. It has been used to potentiate the effect of NO, presumably by potentiating hypoxia-induced pulmonary vasoconstriction. In case of ARDS it is not known whether this combination is useful.
gkk 39
Surfactant therapy• To date no prospective controlled
clinical trial has shown a significant mortality benefit of exogenous surfactant in ARDS
• IV N-Acetyl-Cysteine which may increase the lung surfactants
Newer /Near future Newer /Near future Treatment optionsTreatment options
Newer /Near future Newer /Near future Treatment optionsTreatment options
gkk 41
Anti-inflammatory Strategies
• Antioxidant Therapy -N-acetylcysteine and procysteine, oxygen free-radical scavengers and precursors for glutathione, were efficacious in some experimental studies
• Prostaglandin Agonists/Inhibitors: Prostaglandin E1 is a vasodilator that blocks platelet aggregation and decreases neutrophil activation
• Ibuprofen- an inhibitor of the cyclooxygenase pathway• Ketoconazole, a potent inhibitor of thromboxane and
leukotriene synthesis• Pentoxifylline is a phosphodiesterase inhibitor that
inhibits neutrophil chemotaxis and activation in animal models of ARDS
• Lisofylline inhibited release of TNF, IL-1, and IL-6, • Anti–IL-8 Therapy
gkk 42
Enhanced Resolution of Alveolar Edema
Alveolar fluid clearance depends primarily on active sodium transport across the alveolar epithelium
• Salmeterol, a lipid-soluble ß2-agonist • Intra-alveolar terbutaline administration
markedly increased alveolar fluid clearance • Dobutamine, ß2-adrenergic agonist, markedly
increased alveolar and lung fluid clearance in an experimental rat model
• Dopamine, when administered at 5 µg/kg/min IV, increased alveolar fluid clearance in an isolated perfused rat model by increasing the activity of . Na-K ATP pumps.
gkk 43
Enhanced Repair of the Alveolar Epithelial
Barrier • Studies suggest that hepatocyte
growth factor and keratinocyte growth factor are major mitogens for alveolar epithelial type II cells
gkk 45
Complications• Pulmonary: barotrauma (volutrauma),
pulmonary embolism (PE), pulmonary fibrosis, ventilator-associated pneumonia (VAP).
• Gastrointestinal: hemorrhage (ulcer), dysmotility, pneumoperitoneum, bacterial translocation.
• Cardiac: arrhytmias, myocardial dysfunction.
• Renal: acute renal failure (ARF), positive fluid balance.
gkk 46
Complications
• Mechanical: vascular injury, pneumothorax (by placing pulmonary artery catheter), tracheal injury/stenosis (result of intubation and/or irritation by endotracheal tube.
• Nutritional: malnutrition (katabolic state), electrolyte deficiency.